



# CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.  
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

To,

Date: 14.08.2018

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai -400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.08.2018

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Tuesday at 5:00 p.m. at the registered office of the company at Survey No. 249, Brahmanapally Village, Hayatnagar Mandal - 501511, Telangana the following were considered and approved:

1. Un - Audited financial results for the quarter ended 30.06.2018 alongwith Limited Review Report (Enclosed)
2. 23rd Annual General Meeting of the Shareholders of the Company will be held on Saturday, 29<sup>th</sup> day of September, 2018 at 10:30 a.m. at Survey No.249, Brahmanapally Village, Hayatnagar Mandal R.R.Dist-501511 Telangana,
3. Closure of the Register of Members and Share Transfer Books from 22.09.2018 to 29.09.2018(both days inclusive).
4. E- Voting Period begins on 26.09.2018 and ends on 28.09.2018.

The meeting concluded at 6.00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,  
For Concord Drugs Limited

*S. Nagi Reddy*

S. Nagi Reddy  
Chairman and whole-time Director  
DIN: 01764665



Encl: as above

**STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th JUNE 2018**

[Rs. in Lakhs]

Particulars	Quarterly ended			Year ended 31-Mar-18 (Audited)
	30-Jun-18 (Unaudited)	31-Mar-18 (Audited)	30-Jun-17 (Unaudited)	
<b>I Revenue from Operations</b>				
a. Net sales from Operations	1,303.18	2,109.55	2,097.34	5,179.72
b. Other Operating Income	2.62	18.13	0.98	13.58
<b>Other Income</b>				
<b>Total Revenue (I+II)</b>	<b>1,305.80</b>	<b>2,127.68</b>	<b>2,098.32</b>	<b>5,193.31</b>
<b>III Expenses</b>				
a. Cost of Material Consumed	1,184.58	2,020.46	2,204.31	4,650.17
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	91.22	66.78	326.59	320.38
c. Employees Benefit Expenses	52.72	27.69	55.60	197.42
d. Finance Costs	41.47	63.90	57.80	188.40
e. Depreciation and Amortisation expense	54.16	68.18	54.97	240.14
f. Other expenses	56.97	19.43	46.86	173.68
<b>Total Expenses</b>	<b>1298.69</b>	<b>2266.44</b>	<b>2092.95</b>	<b>5129.44</b>
<b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>	<b>7.11</b>	<b>-138.76</b>	<b>5.37</b>	<b>63.87</b>
<b>V Exceptional Items</b>				
<b>Profit/ (Loss) before tax (V-VI)</b>	<b>(5.66)</b>	<b>(6.13)</b>	<b>6.36</b>	<b>31.45</b>
<b>VII Tax Expense:</b>				
a. Current tax	1.45	0.00	6.36	37.58
b. Deferred tax charge/ credit	7.11	-6.13		6.13
c. MAT Credit				
<b>Profit/ (Loss) for the period (VII-VIII)</b>	<b>12.78</b>	<b>-132.63</b>	<b>-0.99</b>	<b>32.42</b>
<b>IX Other Comprehensive Income</b>				
Items that will not be reclassified to profit or loss				
<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>	<b>12.78</b>	<b>-132.63</b>	<b>-0.99</b>	<b>32.42</b>
<b>XI Paid-up equity share capital</b>	<b>786.18</b>	<b>786.18</b>	<b>786.18</b>	<b>786.18</b>
(Face value of the share- Rs. 10 each)				
<b>XII Other Equity</b>	<b>114.29</b>	<b>1146.14</b>	<b>878.88</b>	<b>1,146.14</b>
<b>XIII Earnings per share (of Rs. 10 each)</b>				
a. Basic (in Rs)	0.16	1.69	-0.01	0.41
b. Diluted (in Rs)	0.16	-1.69	-0.01	0.41

**Notes:**

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) Prescribed under section 133 of the companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14 August, 2018
- The figures of the quarter ended March 31, 2018 are the balancing figures between Audited figures in respect of the full financial year upto March 31, 2018 and the unaudited published year to date figures upto December 31, 2017, which were subjected to limited review by the statutory auditors.
- The company operates in only one Segment viz., "Pharmaceutical Products"
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.

Place: Hyderabad  
Date: 21.08.2018







**Limited review Report on Quarterly unaudited standalone financial results of the Company  
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015**

To  
Board of Directors of  
M/s. Concord Drugs Limited.

We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Concord Drugs Ltd ("the Company") for the quarter ended 30-06-2018, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the 3 months ended 31 March 2018 as reported in this standalone financial results are the balancing figures between audited figures in respect of full previous financial year and the published year to date figures upto the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial had only been reviewed and not subjected to audit.


This statement is the responsibility of the Company's Management and has been approved by the Board of Directors on 14-08-2018. Our responsibility is to issue a report on these financial statements

We conducted our review in accordance with the Standard on Review Engagement ('SRE') 2410, 'Review of Interim Financial Statements performed by the Independent Auditor of the Entity' specified u/s 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Corresponding figures for the quarter ended 30 June 2017 included in the statement were reviewed by the predecessor auditor who expressed an unmodified opinion dated 14 September 2017.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e Ind AS prescribed under section 133 of the companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N G RAO & ASSOCIATES  
Chartered Accountants  
FRNo.009399S

  
Partner: G Nageshwara Rao  
Membership No.207300



Place: Hyderabad  
Date: 14-08-2018